The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

CEO Robert Blum is “very clear” that the company, which is on track for U.S. approval in September for aficamten to treat a ...

Robert Blum. The likelihood now is that Cytokinetics will have to re-align itself around aficamten, currently in the SEQUOIA-HCM pivotal trial which is due to generate results later in 2023 ...

In the press release trumpeting the latest aficamten arrangement, Cytokinetics waxed enthusiastic about the suitability of Sanofi as a partner. It quoted CEO Robert Blum as saying that " We now ...

What Cytokinetics' team, led by CEO Robert Blum, has done in the meantime is nail down a roughly $1 billion funding package in May and land Food and Drug Administration acceptance earlier this ...

Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...

with results expected in the first half of this year as may potentially support the use of aficamten as monotherapy,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In ...

“We have enjoyed a productive collaboration with CORXEL and appreciate all they have done to advance aficamten in Greater China,” said Robert I. Blum, Cytokinetics’ President and CEO.

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.

Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.